Table 3.
Changes of inflammatory cytokines in inflamed mucosa of CD patients before and 10 weeks after IFX treatment.
| Remission group (n = 25) |
Response group (n = 15) |
Failure group (n = 13) |
||
|---|---|---|---|---|
| IFN-γ | Week 0 | 112.6 ± 34.5 | 118.9 ± 32.1 | 117.2 ± 30.4 |
| Week 10 | 32.5 ± 11.2* | 64.7 ± 21.6* | 109.2 ± 32.6 | |
|
| ||||
| TNF | Week 0 | 62.3 ± 12.5 | 63.8 ± 13.2 | 61.8 ± 15.8 |
| Week 10 | 11.5 ± 4.5* | 40.1 ± 8.9+ | 58.9 ± 14.7 | |
|
| ||||
| IL-10 | Week 0 | 8.5 ± 3.6 | 9.8 ± 3.9 | 9.2 ± 3.5 |
| Week 10 | 12.8 ± 2.9 | 12.5 ± 4.1 | 8.9 ± 3.0 | |
|
| ||||
| IL-17A | Week 0 | 35.8 ± 10.5 | 34.6 ± 9.8 | 36.5 ± 8.7 |
| Week 10 | 7.6 ± 3.2* | 18.8 ± 5.2* | 36.7 ± 10.1 | |
|
| ||||
| IL-21 | Week 0 | 21.3 ± 6.3 | 20.1 ± 7.2 | 21.4 ± 6.1 |
| Week 10 | 3.6 ± 1.2* | 11.9 ± 3.5* | 19.8 ± 5.9 | |
|
| ||||
| IL-23p19 | Week 0 | 24.5 ± 6.8 | 25.5 ± 5.4 | 26.9 ± 5.7 |
| Week 10 | 5.8 ± 2.1* | 12.8 ± 4.3+ | 24.5 ± 6.6 | |
|
| ||||
| IL-25 | Week 0 | 8.2 ± 3.2 | 9.8 ± 3.6 | 7.9 ± 3.5 |
| Week 10 | 26.9 ± 8.3* | 15.6 ± 4.8 | 8.8 ± 2.9 | |
|
| ||||
| RORC | Week 0 | 26.1 ± 7.0 | 29.4 ± 8.8 | 25.8 ± 7.3 |
| Week 10 | 7.6 ± 3.5* | 16.7 ± 6.7* | 23.4 ± 5.7 | |
* P < 0.005; + P < 0.05 versus values before initial therapy with IFX.